(EXEL) Exelixis, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(EXEL) Exelixis, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This Exelixis, Inc. BCG Matrix helps you quickly see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio analysis. This page already shows a real preview of the actual report content, so you can review the format before buying. Purchase the full version to get the complete ready-to-use analysis.
Stars
CABOMETYX 1L RCC
CABOMETYX is Exelixis’s lead renal cell carcinoma brand, and it remains the clearest growth engine in the commercial portfolio. In FY2024, Exelixis reported $1.85 billion in net product revenue, with CABOMETYX as the main driver, while the RCC market kept expanding through frontline combination use and line shifts. That mix of strong share and a still-growing oncology setting fits the Star profile.
CABOMETYX HCC
CABOMETYX HCC is a growth star for Exelixis, Inc. because hepatocellular carcinoma is the top liver cancer type, making up about 75%-85% of cases, and treatment demand stays high as regimens keep shifting. CABOMETYX has an established role in this setting, so it keeps adding oncology volume and supports a meaningful share position.
CABOMETYX DTC
CABOMETYX’s differentiated thyroid cancer label adds a smaller but real growth lane beside renal cell carcinoma, which still drives most of Exelixis, Inc.’s franchise sales. The FDA approved CABOMETYX for progressive, radioactive-iodine-refractory DTC in 2021, and the niche keeps extending its commercial reach. That makes it a Star-style asset: a leading product with added upside in an active oncology market.
CABOMETYX combination use
CABOMETYX is Exelixis, Inc.'s key Stars asset because cabozantinib keeps gaining use in front-line and combo regimens across solid tumors. Oncology is moving toward multi-drug treatment, so combination demand should keep the brand growing and defend its share.
- Front-line and combo use support growth
- Multi-drug care lifts cabozantinib demand
- Exelixis keeps CABOMETYX in high-growth settings
Exelixis U.S. cabozantinib franchise
Exelixis, Inc.'s U.S. cabozantinib franchise is the company’s core cash engine and the clearest Star in its BCG mix. In 2024, cabozantinib franchise net product sales were about $1.8 billion, and the product line remained the main source of funding for Exelixis, Inc.'s broader pipeline. Strong oncology brand recognition and durable U.S. demand keep it in a high-share, growth-supporting role.
- Core U.S. revenue driver
- ~$1.8B 2024 franchise sales
- Funds pipeline development
- Strong market recognition
CABOMETYX Powers Exelixis with $1.85B FY2024 Revenue Growth
CABOMETYX is Exelixis, Inc.'s main Star: FY2024 net product revenue was $1.85 billion, and cabozantinib franchise sales were about $1.8 billion. Strong share in renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer keeps it in growth mode.
| Metric | Value |
|---|---|
| FY2024 net product revenue | $1.85B |
| Cabozantinib franchise sales | $1.8B |
| Key growth areas | RCC, HCC, DTC |
What is included in the product
Detailed Word Document
Exelixis BCG Matrix spots Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.
Editable Excel File
One-page Exelixis, Inc. BCG Matrix that clarifies portfolio pain points fast for strategic decisions
Reference Sources
Provides a credible source trail for Exelixis, Inc. that strengthens confidence, speeds review, and supports better decisions.
Cash Cows
CABOMETYX mature base
CABOMETYX’s mature base remains a cash engine for Exelixis, with 2024 net product revenue of about $1.8 billion and broad use in oncology. Because the brand is already well known among oncologists, promotion can stay lighter than in launch years while recurring prescriptions keep cash flowing. That steady base supports BCG cash-cow economics.
Ipsen ex-US cabozantinib royalties
In 2025, Exelixis generated about $1.8 billion of CABOMETYX U.S. net product revenue, and its ex-U.S. Ipsen royalty stream added high-margin cash with little selling cost. That royalty income is mature, steady, and far more predictable than pipeline bets. It fits classic Cash Cow behavior.
MINNEBRO Japan
MINNEBRO Japan is an approved hypertension drug from Exelixis, so it sits in a large but mature market where growth is usually slower than oncology. That makes it more likely to generate steady cash flow than rapid expansion, especially with limited extra investment. In BCG terms, that profile fits a Cash Cow: stable demand, modest growth, and dependable income.
Cabozantinib supply revenue
Cabozantinib supply and collaboration income sits on a mature franchise, not a launch bet. Exelixis reported 2024 total revenue of about $2.1 billion, led by Cabometyx sales, so these receipts can keep generating cash with limited new-market spend.
That fits a Cash Cow because the product is established, widely used, and already monetized. The supply stream adds steady, low-drama revenue while the company focuses on harvesting value from the base.
- Established drug, not a new launch
- Revenue is repeatable and steady
- Low incremental market-building cost
- Supports strong Cash Cow profile
Established partnership economics
Exelixis has long-running partner deals with large pharma names like Bristol Myers Squibb and Ipsen, and mature commercial agreements can throw off steady cash. In FY2024, Exelixis generated over $2B in revenue and held more than $1.5B in cash and investments, so this partnership income helps fund R&D and new trials without straining the balance sheet.
- Long-running licenses support repeat cash inflow.
- Commercialized programs reduce funding risk.
- Cash funds R&D and pipeline trials.
Exelixis’ Cash Cows Keep the Revenue Machine Running
Exelixis’ Cash Cows are led by CABOMETYX and partner royalties: FY2025 CABOMETYX U.S. net product revenue was about $1.8 billion, while total revenue stayed above $2.0 billion. These mature assets need limited extra promotion, but keep producing repeat cash for R&D and pipeline bets. That is classic Cash Cow behavior.
| Cash Cow asset | FY2025 value | Why it fits |
|---|---|---|
| CABOMETYX | ~$1.8B U.S. net product revenue | Mature, steady demand |
| Total revenue | >$2.0B | Harvested cash base |
Preview the Actual Deliverable
Exelixis, Inc. Reference Sources
This preview shows the exact Exelixis, Inc. BCG Matrix document you’ll receive after purchase. No placeholders, no watered-down sample—just the full, ready-to-use report. Download it instantly and use it for strategy, analysis, or presentations with confidence.
Dogs
COMETRIQ capsules
COMETRIQ is Exelixis, Inc.'s older cabozantinib capsule for medullary thyroid cancer, a rare disease that is about 4% of thyroid cancers. CABOMETYX has taken over as the main cabozantinib brand, so COMETRIQ now has limited strategic weight and little growth runway. In BCG terms, that makes COMETRIQ a Dog: low share, low growth.
COTELLIC melanoma franchise
COTELLIC is a mature MEK inhibitor used in advanced melanoma combinations, but the market is crowded and growth is thin. Exelixis no longer relies on this franchise as a key value driver; CABOMETYX has taken the lead in the Company’s product mix. That weak demand profile and low strategic weight fit the Dog quadrant.
Progressive metastatic MTC
Progressive metastatic MTC fits Dog status because medullary thyroid cancer is only about 1%-2% of thyroid cancers, with roughly 5,000 new U.S. cases a year. Even with approval, the total addressable market stays narrow, so Exelixis, Inc. cannot scale this franchise like a broad oncology asset. Low growth and limited share cap long-term upside.
Legacy MEK inhibitor use
Legacy MEK inhibitor use fits the Dogs box because it is an older oncology class, and newer regimens have taken share. Exelixis, Inc. has not signaled this as a growth engine, while its core Kabometyx franchise remains the main revenue driver. In 2025, the class still looks like a low-growth, low-priority area.
In BCG terms, that means limited expansion upside and weaker strategic fit versus newer targeted therapies.
- Older class, slower demand
- Newer rivals have better momentum
- Low growth, low priority
Non-core legacy assets
Exelixis, Inc.’s non-core legacy partnered assets fit the Dog bucket because they are older programs with limited strategic fit and little growth upside. They still need contract tracking, royalty oversight, and partner management, but they do not justify fresh capital because they are unlikely to move the Company Name’s long-term revenue mix.
- Low growth, low strategic fit
- Admin work, limited return
- Keep cash use tightly controlled
Exelixis’ Legacy Assets: Small Market, Little Growth
COMETRIQ and COTELLIC sit in Exelixis, Inc.'s Dogs: older assets with low growth, weak share, and little strategic pull versus CABOMETYX. Medullary thyroid cancer is only about 1%–2% of thyroid cancers, or roughly 5,000 U.S. cases a year, so the market stays narrow. In 2025, these legacy assets add more admin work than revenue growth.
| Asset | 2025 view |
|---|---|
| COMETRIQ | Low share, low growth |
| COTELLIC | Mature, crowded market |
| MTC | ~1%-2% of thyroid cancers |
Question Marks
XL092 zanzalintinib
XL092 (zanzalintinib) is a next-generation multi-kinase inhibitor in Exelixis, Inc.’s pipeline and is still in clinical development, so it has no sales or market share yet. It could extend the cabozantinib franchise into new tumor settings if late-stage data hold up. For now, its growth upside is real, but its lack of commercial revenue makes it a Question Mark in the BCG matrix.
XB002 ADC
XB002 is Exelixis’s tissue factor ADC program, and it sits squarely in the Question Marks bucket because it is still clinical and has no market share yet. ADCs remain a hot oncology field, with 13 FDA-approved ADCs by 2026, so XB002 has real upside if it works. But the program also carries high clinical and commercial risk, so it needs more data before it can move toward a Star.
XL102 CDK7
XL102 is Exelixis, Inc.'s oral CDK7 inhibitor for advanced solid tumors, but CDK7 is still an emerging target, not a mature market. Exelixis is still proving clinical value and differentiation, so XL102 has no commercial share today. That makes it a classic Question Mark: high growth potential, zero current share, and value still tied to clinical readouts.
Pipeline solid tumors
Exelixis, Inc. pipeline solid tumors are Question Marks because they are early and mid-stage bets in crowded oncology markets, where share shifts fast and Phase 3 failure risk is high. In FY2025, Exelixis still leaned on Cabometyx cash flow, with annual net product sales above $2 billion, while R&D kept funding these future assets before any new revenue landed.
- High R&D burn, delayed payback
- Crowded solid-tumor competition
- Phase 3 zanzalintinib risk
The core issue is capital intensity: these programs can add value only if they beat entrenched rivals in hard-to-win tumor settings. Until that proof shows up, they stay classic Question Marks in the BCG Matrix.
Next-gen oncology combinations
Exelixis, Inc. is pushing next-gen oncology combinations with zanzalintinib, testing whether it can win share against bigger cancer players in large Phase 3 settings such as STELLAR-303 and STELLAR-304. The market is big, but commercial proof is still missing, so this fits a Question Mark in the BCG Matrix. Combination therapy still drives most modern oncology wins, but the payoff depends on clear survival and safety data.
- Large market, unproven sales
- Phase 3 data will decide value
- High upside, high execution risk
Exelixis’ Clinical Bets Offer Big Upside, but Zero Sales Yet
Exelixis, Inc.’s Question Marks are XL092, XB002, and XL102: all are still clinical, have no sales, and need Phase 3 proof before they can win share. In FY2025, Exelixis, Inc. still funded these bets with Cabometyx net product sales above $2 billion, so the upside is real but not yet commercial.
| Program | Stage | BCG view |
|---|---|---|
| XL092 | Late-stage | High upside, zero sales |
| XB002 | Clinical | No share yet |
| XL102 | Clinical | Unproven, capital-heavy |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.